Search Results

You are looking at 191 - 200 of 1,210 items for :

  • "characteristics" x
  • Refine by Access: All x
Clear All
Full access

Michael Xiang, A. Dimitrios Colevas, F. Christopher Holsinger, Quynh-Thu X. Le, and Beth M. Beadle

of death to SEER site recode field. Acute toxicities were analyzed within 3 months of the end of RT, as previously described. 13 Statistical Analysis Baseline characteristics were compared using the chi-square or Wilcoxon rank sum test. Multivariable

Full access

Emily van Seventer, J. Peter Marquardt, Amelie S. Troschel, Till D. Best, Nora Horick, Chinenye Azoba, Richard Newcomb, Eric J. Roeland, Michael Rosenthal, Christopher P. Bridge, Joseph A. Greer, Areej El-Jawahri, Jennifer Temel, Florian J. Fintelmann, and Ryan D. Nipp

explore relationships between participant characteristics and muscle, we used multivariable linear regression, including patient age, sex, race, marital status, education level, insurance type, CCI score, time since cancer diagnosis, cancer type, BMI, and

Full access

Michael G. Milligan, Angel M. Cronin, Yolonda Colson, Kenneth Kehl, Debra N. Yeboa, Deborah Schrag, and Aileen B. Chen

characteristics of patients included in our sample, grouped by receipt of brain imaging. Categorical variables were reported as counts and percentages, and groups were compared using chi-square tests for significance. Continuous variables were reported as medians

Full access

Zi-Xian Wang, Hao-Xiang Wu, Ming-Ming He, Ying-Nan Wang, Hui-Yan Luo, Pei-Rong Ding, Dan Xie, Gong Chen, Yu-Hong Li, Feng Wang, and Rui-Hua Xu

clinical outcomes of left- and right-sided CRC tumors. 2 – 7 These differing characteristics are associated with differential prognosis, and patients with right-sided CRC are reported to have a worse prognosis. 8 , 9 A recent meta-analysis including 14

Full access

Claudia S.E.W. Schuurhuizen, Annemarie M.J. Braamse, Aartjan T.F. Beekman, Pim Cuijpers, Mecheline H.M. van der Linden, Adriaan W. Hoogendoorn, Hans Berkhof, Dirkje W. Sommeijer, Vera Lustig, Suzan Vrijaldenhoven, Haiko J. Bloemendal, Cees J. van Groeningen, Annette A. van Zweeden, Maurice J.D.L. van der Vorst, Ron Rietbroek, Cathrien S. Tromp-van Driel, Machteld N.W. Wymenga, Peter W. van der Linden, Aart Beeker, Marco B. Polee, Erdogan Batman, Maartje Los, Aart van Bochove, Jan A.C. Brakenhoff, Inge R.H.M. Konings, Henk M.W. Verheul, and Joost Dekker

-described effective interventions using a stepped care–oriented approach (S). At baseline, the TES and CAU groups were comparable regarding sociodemographic and most clinical characteristics ( Table 1 and supplemental eTable 3 ). Patients in the TES arm received

Full access

William R. Kennedy, Christopher Tricarico, Prashant Gabani, Ashley A. Weiner, Michael B. Altman, Laura L. Ochoa, Maria A. Thomas, Julie A. Margenthaler, Souzan Sanati, Lindsay L. Peterson, Cynthia X. Ma, Foluso O. Ademuyiwa, and Imran Zoberi

for all statistical analyses. Results Patients and Treatment Characteristics A total of 153 patients with a median follow-up of 4.04 years (range, 0.51–13.97 years) were included in the study cohort. Patient characteristics and treatment strategies are

Full access

Brittany Bauman, Rosemarie Mick, Eileen Martinez, Theresa M. Lawless, Lindsey Zinck, Paige Sinclair, Mary Fuhrer, Mark O’Hara, Charles J. Schneider, Peter O’Dwyer, John Plastaras, Ursina Teitelbaum, and Kim A. Reiss

5% type I error rate. Baseline characteristics were summarized for each treatment arm. Continuous variables were summarized by mean, standard error, and range. Categorical variables were summarized by frequency and percentage. Continuous variables

Full access

Davide Mauri, Antonis Valachis, Nikolaos P. Polyzos, Lamprini Tsali, Dimitris Mavroudis, Vassilis Georgoulias, and Giovanni Casazza

analyses could be retrieved from only 13 studies. 10 – 12 , 21 – 30 A flow chart indicating the identification of randomized controlled trials for inclusion in the meta-analysis is reported in Figure 1 . Characteristics of Trials Table 1

Full access

Bishal Gyawali, Elvira D’Andrea, Jessica M. Franklin, and Aaron S. Kesselheim

patient and disease characteristics closest to those of the RCT. If a non-RCT contained multiple arms for different doses or different histologies, we chose the dose and tumor cohort with the nearest match to the RCT. If the trial characteristics were

Full access

Walburga Yvonne Joko-Fru, Mirko Griesel, Nikolaus Christian Simon Mezger, Lucia Hämmerl, Tobias Paul Seraphin, Jana Feuchtner, Henry Wabinga, Guy N’da, Assefa Mathewos, Bakarou Kamaté, Judith Nsonde Malanda, Freddy Houéhanou Rodrigue Gnangnon, Gladys Chebet Chesumbai, Anne Korir, Cesaltina Lorenzoni, Annelle Zietsman, Margaret Ziona Borok, Biying Liu, Christoph Thomssen, Paul McGale, Ahmedin Jemal, Donald Maxwell Parkin, and Eva Johanna Kantelhardt

evidence of receiving any CDT For patients with metastatic disease, we described the therapy they received (see Table 1 for therapies). Table 1. Therapy Characteristics for Patients With BC by Stage at Diagnosis Assessing Loss to Follow